Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04598269 | Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis | PHASE2 | COMPLETED | 50 | — | — | Sep 30, 2020 | Apr 22, 2021 | Sep 28, 2023 | 14 | United States |
The EASI evaluation was performed by the Principal Investigator and evaluated atopic dermatitis in each of 3 body regions (trunk \[excluding groin and genitalia\], upper extremities \[excluding palms of hands\], and lower extremities \[excluding soles of feet\]). The EASI scoring system uses a defined process to grade the severity of the signs of atopic dermatitis and the extent affected. EASI Scores ranged from 0-72, with higher scores indicative of more severe disease.
| Arm | Type | Description |
|---|---|---|
| ATI-1777 | EXPERIMENTAL | ATI-1777 topical solution 2.0% w/w, twice daily |
| Vehicle | PLACEBO_COMPARATOR | Vehicle topical solution, twice daily |
| Name | Type | Description |
|---|---|---|
| ATI-1777 | DRUG | ATI-1777 topical solution 2.0% w/w |
| Vehicle | DRUG | Vehicle topical solution containing no ATI-1777 |
Inclusion Criteria: 1. Able to comprehend and willing to sign the IRB approved informed consent form (ICF) prior to administration of study-related procedures. 2. Male patients or non-pregnant, non-nursing female patients 18 to 65 years old, inclusive, at the time of informed consent. 3. Pregnancy ...